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doi:10.1016/j.ejvs.2008.10.007Abstract Background: Uncertainty exists on whether there is adjuvant benefit of percuta-
neous transluminal angioplasty (PTA) over supervised exercise and best medical therapy in
the treatment of intermittent claudication.
Methods: Patients with symptoms of stable mild to moderate intermittent claudication (MIMIC)
were randomised in two multi-centre trials, for femoropopliteal and aortoiliac arterial disease,
to receive either PTA or no PTA against a background of supervised exercise and best medical
therapy and followed up for 24 months. Initial claudication distance (ICD) and absolute walking
distance (AWD) on treadmill were compared between randomised groups adjusting for the cor-
responding measure at baseline. Secondary outcomes included ankle-brachial pressure index
(ABPI) and quality of life.
Findings: A total of 93 patients were randomised into the femoropopliteal trial (48 into PTA) and
34 into the aortoiliac trial (19 to PTA). Themean (standard deviation, SD) age was 66(9) years for
the femoropopliteal trial (63% male) and 63(9) for the aortoiliac trial (65% male). At 24 months,
there were significant improvements in both AWD and ICD in the PTA groups for both trials. The
adjusted AWD was 38% greater in the PTA group for the femoropopliteal trial (95%; CI 1e90)
(pZ 0.04) and 78% greater in the PTA group for the aortoiliac trial (95%; CI 0e216) (pZ 0.05).
Further benefits were demonstrated for ABPI but not for quality of life.Greenhalgh, Imperial College London, Vascular Surgery Research Group, Charing Cross Hospital
W6 8RF, UK
erial.ac.uk
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Adjuvant Benefit of Angioplasty in Patients with MIMIC 681Interpretation: PTA confers adjuvant benefit over supervised exercise and best medical therapy
in terms of walking distances and ABPI 24 months after PTA in patients with stable mild to
moderate intermittent claudication.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.There is a category of patients with lower limb occlusive
peripheral arterial disease whose symptom of intermittent
claudication (pain in the legs on physical exertion) may be
alleviated by balloon angioplasty. Percutaneous trans-
luminal angioplasty (PTA) has been compared with medical
therapy and supervised exercise in two separate, rando-
mised, controlled trials; a Cochrane review of these trials
has concluded that there may be a short-term benefit with
PTA, but there is inconclusive evidence on whether the
improvement is sustained in the long term.1e5 Since these
trials were performed, evidence on the beneficial effects of
exercise has been demonstrated in a number of studies,
with two Cochrane reviews highlighting the value of exer-
cise in patients with intermittent claudication.6e8 Further
reviews have confirmed the benefit of supervised over non-
supervised exercise.9,10
Stents are routinely used to treat iliac occlusions.
However, there are no data to support the routine use of
stents for iliac stenoses. Stents are therefore reserved for
lesions where angioplasty has left a significant residual
stenosis.11 Evidence for the use of stents in the femo-
ropopliteal segment is more controversial as the length of
the lesion may determine whether it is beneficial.12e14
However, uncertainty remains on the efficacy of PTA (with
or without stent) over and above treatment with supervised
exercise and best medical therapy which have both been
shown to benefit patients with intermittent claudication.
Thus, the multi-centre, randomised mild to moderate
intermittent claudication (MIMIC) trials were instigated to
test the effect of adjuvant PTA over supervised exercise,
smoking cessation advice and best medical therapy in
patients with stable, mild to moderate symptoms of inter-
mittent claudication caused by aortoiliac or femo-
ropopliteal lesions suitable for PTA. The outcomes were
specified in terms of treadmill walking distances, ankle-




Patients presenting with symptoms of stable intermittent
claudication, both new referrals or existing outpatients,
were registered and screened for trial suitability, including
completion of the Edinburgh Claudication Questionnaire.15
For trial purposes, the definition of MIMIC was calf or
buttock pain on walking: mild enough for intervention not
to be considered mandatory, yet severe enough for both
patient and doctor to consider balloon angioplasty. Stability
was determined at a local level by the clinical team using
the suggested guideline of a 3-month history of pain on
walking despite optimisation of best medical therapy andsmoking cessation. The choice of target lesion was deter-
mined by the local clinician primarily on the basis of duplex
mapping, and patients could only be entered into one of
the two trials: an aortoiliac disease trial or femoropopliteal
trial. Fig. 1 shows the trial design.
Inclusion and exclusion criteria
Entry criteria were the same for both the aortoiliac and
femoropopliteal trials. There were no age or gender
restrictions on trial participation. Suitable patients
required a positive outcome on the Edinburgh Claudication
Questionnaire, ABPI <0.9 or >0.9 with a positive stress test
(a fall of >30 mmHg in Doppler blood pressure following
a treadmill test at 4 km h1, 10 slope for 1 min16) and
either an aortoiliac or a femoropopliteal target lesion
amenable to PTA as demonstrated by duplex mapping or
diagnostic arteriography. Patients were excluded if symp-
toms were too mild to consider angioplasty or so severe
that intervention was mandatory. Patients with critical limb
ischaemia (absolute Doppler blood pressure <50 mmHg or
presence of ulcers or gangrene with a Doppler pressure
>50 mmHg) or concomitant disease such as musculoskeletal
or cardiac which was prohibitive to exercise were also
excluded.
Randomisation
Randomisation was performed for each trial separately and
used a 1:1 ratio in randomly permuted blocks of unequal
size generated by Stata version 8.0 (Stata Corporation,
Texas, USA). Randomisation was stratified by centre and
was performed by the trial manager via a laptop computer
whilst on site at each centre after obtaining informed
consent and completion of the baseline assessment.
Treatment allocation was to either ‘angioplasty, supervised
exercise and best medical treatment’ or ‘supervised exer-
cise and best medical therapy alone’ within the aortoiliac
trial or femoropopliteal trial depending on the location of
the target lesion.
Procedures and interventions
Allocated treatments started immediately after random-
isation, with angioplasty performed as soon as possible to
coincide with the start of supervised exercise and within
3 months. Follow-up was at 6 months, 12 months and 24
months after randomisation. The trial manager, liaising
with individual centre coordinators, was responsible for
all aspects of patient recruitment and collection of
follow-up data, attending each centre fortnightly in
rotation. All data were held centrally at Charing Cross
Hospital, London, UK.
Patients with stable mild to moderate intermittent claudication
ABPI < 0.9, or ABPI >0.9 with positive stress test
Assessment by Duplex mapping or
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Figure 1 Schematic of trial design.
682 The MIMIC Trial ParticipantsSupervised exercise
All centres were provided with a standardised protocol of
supervised exercise which was effective in the pilot
study.17 This consisted of a 30-min continuous exercise
session to a maximum pain threshold, using a walking
circuit interspersed with seven lower limb training stations
(e.g., stair climbing, heel raises and treadmill walking) and
was supervised by physiotherapists or nursing staff. The
classes were offered at least once per week, and all
patients were asked to attend one or more sessions per
week for 6 months and also encouraged to increase their
daily exercise levels.
Smoking cessation advice
The importance of smoking cessation was stressed to all
patients, and nicotine replacement therapy was prescribed
where necessary. Smoking status was assessed using
patient-reported habit and serum cotinine levels, which,
as a stable metabolite of nicotine with a relatively long
half-life, has been shown to be a reliable indicator of
exposure to nicotine. Self-reported smoking status was
measured for all follow-up appointments, whilst cotinine
was measured at baseline and 24 months to assess long-
term smoking cessation rates and validate self-reported
smoking status.Best medical therapy
Optimisation of best medical therapy was required for all
participants. Blood pressure using standard cuff sphygmo-
manometry, total and high-density lipoprotein (HDL) serum
cholesterol, serum glucose and anti-platelet treatment
were assessed at baseline, and drug therapy was
commenced where necessary. The general practitioner
(GP) was notified for continuity of prescriptions. The
threshold levels for instigating therapy were: blood pres-
sure of >140/85 mmHg (>135/80 mmHg for patients with
diabetes), total cholesterol >5 mmol/L and serum glucose
>7.3 mmol/L (fasting) or >11.1 mmol/L (random). All
patients, with no contraindications for anti-platelet use,
were recommended to take aspirin (75 mg) or clopidogrel if
intolerant to aspirin. Current medications were recorded at
each follow-up to track compliance with therapy, and
cholesterol was checked again at 24 months.
Percutaneous transluminal angioplasty (PTA)
PTA involves the inflation of a balloon catheter at the site
of arterial narrowing to increase the lumen size. After
arterial vascular access is achieved, heparin is administered
and the diseased segment is traversed with a guide wire
before inflation. For unsatisfactory results, a stent is
sometimes used.
Adjuvant Benefit of Angioplasty in Patients with MIMIC 683Duplex ultrasound scanning of the iliac arteries can be
inaccurate if there is extreme arterial calcification or
significant bowel gas impairing the scan image. Thus,
accuracy of the baseline duplex examination of the iliac
arteries was checked by using a diagnostic angiogram of the
pelvis and lower limbs before any intervention. The
severity of disease in the iliac arteries of the index limb was
measured angiographically as a percentage stenosis.
A resting pressure gradient along the iliac segment was
assessed by either pull-back technique or using simulta-
neous catheters in the common femoral artery and aorta. If
a resting pressure gradient of less than 10 mmHg was
identified, interventionists were asked to repeat the
measurement after vasodilatation using 30 mg of papav-
erine injected down the index limb. These angiographic
findings were used to identify any patients with significant
disease undetected by duplex ultrasound scanning. Patients
who were randomised to femoropopliteal intervention but
found to have significant aortoiliac disease had to be
treated with aortoiliac angioplasty (with or without stent)
in preference, followed by the femoropopliteal procedure.
Use of a stent for aortoiliac lesions was left to the discre-
tion of the local operator. For the femoropopliteal lesions,
use of a stent was permitted only if there was an unsatis-
factory improvement after plain angioplasty of the lesion.
Outcome measures
The primary outcome measure was AWD in metres at 24
months. AWD is defined as the maximum distance that
patients can walk before they have to stop either due to
claudication pain or for any other reason such as breath-
lessness or fatigue. It was measured on a treadmill machine
set at a 10 incline running at 4 km h1, up to a maximum of
15 min (i.e., 1000 m). Secondary outcomes were: AWD at 6
months and 12 months; ICD, defined as the distance the
patient walks on the treadmill before onset of claudication
pain; ABPI in the target limb and quality of life assessed
using the Short-Form 36 questionnaire18 with the eight
domains summarised using the mental and physical
summary scales.
Ethical approval
Ethical approval was obtained from the North West Multi-
centre Research Ethics Committee and site-specific approval
was granted locally at each centre. An international standard,
randomised, controlled trial number (ISRCTN) was allocated
e 37194085. All adverse events were reported to the Data
Monitoring and Ethical Committee.
Statistical methods
The intended recruitment was for 170 patients in each trial.
This was based on achieving 90% power to detect, at a 5%
significance level, an improvement of 60 m in AWD for the
PTA group compared to the control group at 24 months. The
SD of AWD was assumed to be 120 m, with a correlation
between baseline and follow-up of 0.5, and the target
recruitment allowed for 15% loss to follow-up and a 5%
cross-over rate between the randomised groups.The analysis was carried out according to a pre-specified
plan, based on intention-to-treat principles, for each trial
separately. The primary outcomewas the AWD at 24months.
The AWD was log transformed to achieve approximate
normality; averages are reported as geometric means, and
comparisons of groups as ratios. The few values of AWD
>1000 m were taken as equal to 1000 m. The principal
analysis of each outcome involved regression adjustment for
the corresponding measure at baseline, together with age,
sex, baseline smoking status and ABPI. The ICD was consid-
ered as censored by the AWD if claudication pain had not
been reported by then, and so assessed using survival anal-
ysis methods (KaplaneMeier curves and Cox regression).
Role of the funding source
These trials were funded by the Camelia Botnar Arterial
Research Foundation with independent educational grants
from Bard Ltd., Boston Scientific Ltd. and Cook. Neither
the study sponsor nor funding bodies had any role in the
study design, data collection, data analysis, data inter-
pretation or writing of the report. The corresponding
author had full access to all of the data from the study and
had final responsibility for submission of the publication.
Results
Recruitment
Over a 31-month period from August 2003 to February 2006,
1401 patients from nine UK centres were considered
for inclusion in the trials. Recruitment was slower than
anticipated and stopped early in order to complete the
24-month follow-up of the patients already enrolled with
the available funding. Of those enrolled, 144 (10%) patients
were eligible for the trials; major reasons for ineligibility
were patients refusal (20%), failure to meet the Edinburgh
Claudication Questionnaire criteria (19%), failure to meet
the ABPI criteria (10%), unsuitable lesion (8%), being unable
to walk on a treadmill (8%) or PTA being considered
mandatory (7%). Of the 144 patients, 127 consented to the
trial and were randomised in either the femoropopliteal or
aortoiliac trial. Fig. 2 shows the flow of patients through
the trials. The overall attendance at 24 months was 83%
(losses shown in Fig. 2); of those attending, 89% were
treadmill tested. The reasons that treadmill tests could not
be performed were cardiovascular (such as unstable heart
disease or angina) or non-vascular (such as chest infection,
twisted ankle or balance problems) in roughly equal
proportions.
Table 1 shows the baseline comparability of the patients
in each trial. In the femoropopliteal trial, there were slight
imbalances due to chance in mean age, history of ischaemic
heart disease (IHD) and use of statins. There were no
apparent imbalances in the aortoiliac trial.
Femoropopliteal trial
Among the 48 patients randomised to PTA, PTA was not
attempted in four patients (e.g., because symptoms
improved). In the remaining 44, PTA was carried out in
19 in PATA 15 in Control48 in PTA 
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45 in Control
144 suitable for trials
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Figure 2 CONSORT diagram showing flow of patients through trials.
684 The MIMIC Trial Participantsa median (interquartile range, IQR) of 48 (32e80) days
after randomisation. In 11 patients, the PTA was recorded
as ‘failed’ by the local radiologist. Of the 33 successful
PTAs, 21 were of the target lesion alone, seven were of
a target and of a non-target lesion (mostly other femo-
ropopliteal lesions), and five were of a non-target lesion
alone (all aortoiliac lesions). No stents were used for any
femoropopliteal angioplasties but for two patients who
also underwent an additional aortoiliac angioplasty,Table 1 Baseline characteristics of patients entered into the M
Femoropopliteal trial
Control (nZ 45) P
Age (years) 68.5 (9.4) 6
Body mass index (kg m2) 26.9 (4.5) 2
AWD (m)a 126 (62)
ICD (m)a 63 (30)
ABPI 0.69 (0.12) 0
SF36 physical health score 39.7 (7.4) 3
SF36 mental health score 47.6 (12.5) 5
Male 26 (58)
Ever smoker 38 (84)
Past history of hypertension 34 (76)
Past history of IHD 10 (22)
Using statins 30 (67)
Using antiplatelets 40 (89)
AWD absolute walking distance, ICD initial claudication distance, ABPI
short-form 36 summary scores.
a Geometric mean (approximate SD).a stent was placed in this segment. Four patients of the 44
randomised to the control group went on to receive PTA
(all of the target lesion) during the follow-up period.
There were very few complications following the angio-
plasty procedures: five minor haematomas and one
dissected artery. Similarly, there were few adverse events
in either group with no myocardial infarctions: two strokes
and two distal bypass graft operations during the course of
24 months follow-up. Both randomised groups attendedIMIC trials, mean (SD) or number (%).
Aortoiliac trial
TA (nZ 48) Control (nZ 15) PTA (nZ 19)
3.9 (9.0) 62.5 (9.8) 63.9 (8.6)
7.0 (5.1) 25.2 (3.8) 27.2 (3.6)
133 (77) 126 (53) 114 (87)
71 (41) 64 (20) 49 (38)
.66 (0.14) 0.66 (0.11) 0.68 (0.19)
8.9 (8.5) 37.7 (8.2) 38.3 (9.0)
0.4 (11.2) 44.0 (11.4) 43.1 (12.2)
33 (69) 10 (67) 12 (62)
38 (79) 15 (100) 17 (89)
35 (73) 8 (53) 11 (58)
21 (44) 6 (40) 5 (26)
40 (83) 12 (80) 11 (58)
44 (92) 11 (73) 16 (84)
ankle-brachial pressure index, IHD ischaemic heart disease, SF36
Figure 3 Geometric mean absolute walking distance (AWD) by randomised group and time in the femoropopliteal trial
(mean standard error plotted on log scale).
Adjuvant Benefit of Angioplasty in Patients with MIMIC 685a similar proportion of the available weekly supervised
exercise classes (means: 62% PTA and 61% control). Self-
reported smoking status (confirmed by serum cotinine)
and drug treatment remained stable throughout the trial,
except that statin use increased in both groups from an
average at baseline of 75% to an average of 88% during
follow-up.
The geometric mean AWD in each randomised group over
time is shown in Fig. 3. The mean AWD increased in bothTable 2 Outcomes in the MIMIC femoropopliteal trial.
Control PTA
AWD (geometric mean, metres)
6 Months (nZ 81) 167 202
12 Months (nZ 75) 150 224
24 Months (nZ 71)a 155 245
ICD (% attaining 200 m
without claudication pain)
6 Months (nZ 81) 23% 32%
12 Months (nZ 75) 25% 42%
24 Months (nZ 71) 22% 63%
Other outcomes at 24 months
Mean ABPI (nZ 73) 0.72 0.83
Mean SF36 physical score (nZ 79) 39.2 40.9
Mean SF36 mental score (nZ 79) 47.6 51.5
AWD absolute walking distance, ICD initial claudication distance, A
scores.
a Pre-specified primary outcome.
b Adjusted for corresponding measure at baseline, age, sex, baselin
c Hazard ratio for comparing probabilities of attaining a particulargroups after baseline, but to a greater extent in the PTA
group. Comparing the PTA with the control group, the ratio
of geometric mean AWD at 24 months (the primary
outcome) was 1.58 (i.e., a 58% increase, Table 2). This ratio
was reduced to 1.38 (i.e., a 38% increase, pZ 0.04) on
adjustment for baseline variables, principally because of
the age imbalance.
The secondary outcome variables are also shown in
Table 2. The ratios of geometric mean AWD, comparing PTAAdjusted result
(95% CI) p-valueb
Ratio PTA:control
1.21 1.06 (0.80e1.41) pZ 0.69
1.49 1.22 (0.88e1.67) pZ 0.23
1.58 1.38 (1.01e1.90) pZ 0.04
Hazard ratio
PTA:control c
1.56 1.78 (0.99e3.21) pZ 0.05
2.18 2.18 (1.15e4.12) pZ 0.02
2.83 3.11 (1.42e6.81) pZ 0.004
Difference:
PTAcontrol
0.11 0.11 (0.03e0.20) pZ 0.01
1.7 0.4 (4.2 to 3.4) pZ 0.82
3.9 2.4 (1.7 to 6.5) pZ 0.25
BPI ankle-brachial pressure index, SF36 short-form 36 summary
e smoking status and ABPI.
ICD (see Fig. 4).
Figure 4 Initial claudication distance (ICD) at 24 months by randomised group in the femoropopliteal trial (KaplaneMeier
probability of attaining a given distance without claudication pain).
686 The MIMIC Trial Participantsto control, at both 6 months and 12 months were also
greater than 1, but to a lesser degree than at 24 months,
and these differences were not statistically significant. The
probability of attaining a specified ICD at 24 months is
shown in Fig. 4; for example, the probabilities of attaining
200 m without claudication pain are 63% and 22% in the PTA
and control groups, respectively. Expressed as hazard ratios
(Table 2), the differences in ICD were statistically signifi-
cant at all three follow-up times. The mean ABPI was
significantly higher in the PTA group at 24 months, while theTable 3 Outcomes in the MIMIC aortoiliac trial.
Control PTA
AWD (geometric mean, metres)
6 Months (nZ 27) 178 316
12 Months (nZ 24) 167 319
24 Months (nZ 23)a 168 354
ICD (% attaining 200 m
without claudication pain)
6 Months (nZ 27) 0% 60%
12 Months (nZ 24) 18% 58%
24 Months (nZ 23) 25% 61%
Other outcomes at 24 months
Mean ABPI (nZ 25) 0.74 0.90
Mean SF36 physical score (nZ 25) 38.6 46.4
Mean SF36 mental score (nZ 25) 46.0 50.3
AWD, absolute walking distance; ICD, initial claudication distance; A
scores.
a Pre-specified primary outcome.
b Adjusted for corresponding measure at baseline, age, sex and ABP
c Hazard ratio for comparing probabilities of attaining a particularphysical and mental scores from the SF36 quality-of-life
scale showed no significant differences.
Sensitivity analyses were carried out that: (1) addition-
ally adjusted for baseline history of IHD and statin use
(these being apparently imbalanced); (2) adjusted for
baseline serum cotinine level rather than for reported
smoking status; (3) adjusted for attendance at supervised
exercise classes; (4) removed potential outliers from some
of the analyses; (5) compared ICD using geometric means
(replacing it by the AWD when claudication pain had notAdjusted result
(95% CI) p-valueb
Ratio PTA:control
1.78 1.75 (1.02e3.02) pZ 0.04
1.91 1.77 (0.93e3.37) pZ 0.08
2.11 1.78 (1.00e3.16) pZ 0.05
Hazard ratio
PTA:control c
3.2 3.9 (1.3e11.6) pZ 0.01
3.2 3.9 (1.1e13.6) pZ 0.04
3.1 3.6 (1.0e12.8) pZ 0.05
Difference:
PTAcontrol
0.16 0.14 (0.03e0.26) pZ 0.02
7.8 7.8 (1.5e14.1) pZ 0.02
4.3 4.9 (e1.3 to 11.1) pZ 0.12
BPI, ankle-brachial pressure index; SF36, short-form 36 summary
I (but not smoking status because of zero cells in some groups).
ICD.
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successful PTA in the PTA group to patients without PTA in
the control group. These analyses did not change the
interpretation of the results presented.
Aortoiliac trial
For the 19 patients in the aortoiliac trial randomised to
receive PTA, 17 had successful PTA of the target lesion.
Amongst the 15 patients in the control group, four went on
to receive PTA later during the follow-up period. A total of
five stents were used across all the aortoiliac angioplasties
(four in the target lesion and one in a non-target aortoiliac
lesion). There were very few complications following the
angioplasty procedures: three minor haematomas and one
sensory deficit. Similarly, there were few adverse events in
either group with no myocardial infarctions, two strokes
and no distal bypass graft operations during the course of
the 24 months follow-up. Both groups attended a similar
proportion of the available weekly exercise classes (means:
53% PTA, 48% control). The results of the aortoiliac trial are
summarised in Table 3. Despite the small size of the trial,
resulting in wide confidence intervals, there were statisti-
cally significant improvements in the PTA group for AWD,
ICD, ABPI and the SF36 physical score.
Discussion
The results achieved for these trials are surprisingly
convincing despite the low recruitment rate and low rate of
eligibility, and therefore one might question whether the
trials are truly representative of the intended patient
population. There were a number of reasons for the poor
recruitment, mainly relating to the UK funding system of
health care placing the budget with the primary care groups
so that referral to secondary care has become less certain.
For aortoiliac disease, many clinicians were unprepared to
test the efficacy of angioplasty as they believed strongly
that it worked. These data appear to confirm their preju-
dice. Moreover, it is interesting that results are apparently
more impressive at 24 months than at 6 or 12 months as the
earlier Cochrane review had cast some doubt on the long-
term efficacy of angioplasty.5 From a safety perspective, it
is encouraging that the rates of complication and adverse
events were low for both trials. In terms of cost-effec-
tiveness, Spronk et al. previously have reported that PTA is
unlikely to be cost-effective when compared with super-
vised exercise19; however, further analyses are required on
whether the benefit presented here is cost-effective.
In our trials, best medical treatment and smoking
cessation advice as well as mandatory supervised exercise
were prerequisites before balloon angioplasty. We consid-
ered this imperative particularly as there are two large
well-conducted studies suggesting that statins themselves
can improve walking times.20,21 Thus, lipid modification to
recognised standards was ensured in all study participants.
There is no evidence that angioplasty alone would produce
similar results, although we await the results of the CLEVER
Trial which has commenced recently in the United States.22
In the latter trial, which intends to recruit 250 patients with
claudication from aortoiliac disease, a comparison is
proposed between four randomised treatment groups ofmedical therapy, stent placement, supervised exercise and
all treatments combined.
The previous Oxford1,2 trial compared angioplasty to
supervised exercise, and the Edinburgh trial 3,4 compared
angioplasty with medical therapy to medical therapy alone;
both were smaller than the current trials. The Oxford and
Edinburgh trials reported results differently, but baseline
walking distances appeared to be very comparable with the
trials presented here. However, their impact was to place
a question mark regarding angioplasty as a form of long-
term treatment, particularly as the 6-year results for the
Oxford trial did not suggest any improvement with PTA.2
Our results provide promising evidence that the benefit of
adjuvant PTA over supervised exercise may now be sus-
tained for a considerable period of time.
It is noteworthy that the femoropopliteal results were
achieved without the use of stents. Since the start of the
MIMIC trials, evidence has emerged on the potential benefit
of stent over plain angioplasty in the femoropopliteal
segment23,24; however, other research shows that the
length of lesion may play an important role in the level of
benefit.12e14 Our MIMIC trial provides no evidence on stents
in the femoropopliteal segment as none were used. Oper-
ators, however, were not prepared to be denied the use of
stent if considered necessary in the aortoiliac segment.
Conclusion
Despite some reservations relating to generalisability, these
findings lend weight to the value of angioplasty as a treat-
ment for intermittent claudication for up to 24 months, on
a background of best medical treatment and supervised
exercise, in MIMIC whether caused by aortoiliac or femo-
ropopliteal disease.
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